Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Neuronetics, Inc.NASDAQ: STIM
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 37.7% from a year ago
Cash & equivalents stood at $13.21M at the end of Q1 FY2026, down 37.7% from a year earlier and down 61.3% from the prior quarter. Over 3 fiscal years it compounded at -21.4% a year.
Context
- Cash & equivalents amounted to 10.5% of total assets at the end of Q1 FY2026, down 4.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -37.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 34.13M USD
- Year-over-year change
- +75.4%
- 4-year CAGR
- -22.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.13M | +75.4% |
| FY2024 | 2024-12-31 | 19.46M | -67.4% |
| FY2023 | 2023-12-31 | 59.68M | -15.2% |
| FY2022 | 2022-12-31 | 70.34M | -25.3% |
| FY2021 | 2021-12-31 | 94.14M | — |
Cash & Equivalents vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -37.7% is the 8th highest of 10, against a peer median of +9.6%.
- Cash & equivalents amounts to 10.5% of total assets for STIM, versus a peer median of 28.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $176.96M USD | -28.5% | +33.4% | 46.7% | |
| Mar 2026 | $56.02M USD | +16.8% | -39.7% | 32.0% | |
| Mar 2026 | $53.97M USD | +21.5% | +13.4% | 13.1% | |
| Mar 2026 | $50.46M USD | +8.7% | +20.7% | 68.5% | |
| Mar 2026 | $37M USD | +102.0% | -23.6% | 28.6% | |
| Mar 2026 | $29.05M USD | +166.7% | -8.6% | 9.9% | |
| Mar 2026 | $27.59M USD | +9.6% | -40.7% | 46.0% | |
| Mar 2026 | $13.21M USD | -37.7% | -21.4% | 10.5% | |
| Mar 2026 | €12.98M EUR | -42.0% | +18.8% | 13.3% | |
ATLNAtlantic International Corp. | Dec 2025 | $81.13K USD | -88.0% | -66.6% | 0.1% |
| Peer median (excluding STIM) | — | +9.6% | -8.6% | 28.6% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 94.14M | 70.34M | 59.68M | 19.46M | 34.13M |
| Short-term Investments | 2.2M | 1.54M | 905K | 206K | 225K |
| Net Receivables | 7.78M | 13.82M | 17.84M | 24.29M | 16.89M |
| Inventory | 6.56M | 8.9M | 8.09M | 4.25M | 4.33M |
| Other Current Assets | 3.09M | 2.17M | 4.77M | 6.85M | 5.97M |
| Total Current Assets | 115.33M | 98.77M | 93.79M | 58.12M | 61.55M |
| Property, Plant & Equipment (Net) | 5.1M | 5.32M | 4.78M | 33.34M | 28.03M |
| Goodwill | 0 | 0 | 0 | 18.63M | 23.62M |
| Intangible Assets | 0 | 0 | 0 | 19.61M | 18.15M |
| Long-term Investments | 1.7M | 1.22M | 661K | 86K | 249K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 19.09M | 11.58M | 16.6M | 11.12M | 9.95M |
| Total Non-current Assets | 25.89M | 18.12M | 22.04M | 82.78M | 80M |
| Total Assets | 141.22M | 116.88M | 115.83M | 140.9M | 141.55M |
| Account Payables | 4.3M | 2.43M | 4.75M | 11.08M | 10.74M |
| Short-term Debt | 0 | 13.13M | 0 | 0 | 5.56M |
| Tax Payables | 664K | 659K | 818K | 619K | 0 |
| Deferred Revenue | 2.5M | 1.98M | 1.62M | 974K | 753K |
| Other Current Liabilities | 5.09M | 11.2M | 8M | 8.95M | 4.86M |
| Total Current Liabilities | 15.7M | 33.2M | 19.81M | 31.27M | 30.52M |
| Long-term Debt | 35.34M | 22.83M | 59.28M | 55.15M | 65.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.47M | 829K | 200K | 2K | 48K |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 40.35M | 26.63M | 61.83M | 77.84M | 84.79M |
| Total Liabilities | 56.05M | 59.82M | 81.64M | 109.1M | 115.31M |
| Common Stock | 264K | 273K | 291K | 557K | 690K |
| Retained Earnings | (308.73M) | (345.89M) | (376.08M) | (419.79M) | (458.79M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 4.09M | 3.86M |
| Total Equity | 85.18M | 57.06M | 34.19M | 31.8M | 26.24M |
| Total Debt | 39.54M | 39.75M | 62.47M | 82.63M | 90.3M |
| Net Debt | (54.6M) | (30.6M) | 2.8M | 63.17M | 56.17M |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.